Efficiency of Fenofibrate in Facilitating the Reduction of Central Macular Thickness in Diabetic Macular Edema
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 3, Pages 3160-3164
AbstractBackground: Diabetic macular edema (DME) has been reported at rates of 10% and occurs more frequently in type 2 diabetes mellitus. The present study was conducted to assess the efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema.
Materials & Methods: 60 patients with type 2 diabetes having treatment naïve, center‑involving DME of both genders were divided into 2 groups. Group I had DME only in one eye and group II had DME in both eyes. Group I were given oral fenofibrate 160 mg/day for 6 months as a single evening dose. Central macular thickness in both groups was compared.
Results: The mean FBS was 137.6 mg/dl in group I and 158.2 mg/dl in group II, PPBS was 210.4 mg/dl and 238.6 mg/dl, blood urea (mg/dl) was 29.3 in group I and 31.5 in group II and serum creatinine (mg/dl) was 0.92 and 0.99 in group I and in group II respectively. CMT in group I and group II at baseline was 432.6 and 402.1, at 2 months was 360.2 and 358.1, at 4 months was 327.5 and 331.4 and at 6 months was 294.3 and 317.6 in group I and in group II respectively. The difference was non- significant (P>0.05).
Conclusion: Fenofibrate facilitate reduction of central macular thickness in patients with diabetic macular edema
- Article View: 29
- PDF Download: 85